key: cord-0716863-gw8bo7aw authors: Kato, Yuri; Yamada, Shigeru; Nishiyama, Kazuhiro; Satsuka, Ayano; Re, Suyong; Tomokiyo, Daiki; Lee, Jae Man; Tanaka, Tomohiro; Nishimura, Akiyuki; Yonemitsu, Kenzo; Asakura, Hiroshi; Ibuki, Yuko; Imai, Yumiko; Kamiya, Noriho; Mizuguchi, Kenji; Kusakabe, Takahiro; Kanda, Yasunari; Nishida, Motohiro title: Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry date: 2021-03-14 journal: bioRxiv DOI: 10.1101/2021.03.13.435221 sha: 9c7a7c7e0f4d5aede6eb907b8e06dd82ac0a514d doc_id: 716863 cord_uid: gw8bo7aw Myocardial damage caused by the newly emerged coronavirus (SARS-CoV-2) infection is one of key determinants of COVID-19 severity and mortality. SARS-CoV-2 entry to host cells are initiated by binding with its receptor, angiotensin converting enzyme (ACE) 2, and the ACE2 abundance is thought to reflect the susceptibility to infection. Here, we found that clomipramine, a tricyclic antidepressant, potently inhibits SARS-CoV-2 infection and metabolic disorder in human iPS-derived cardiomyocytes. Among 13 approved drugs that we have previously identified as potential inhibitor of doxorubicin-induced cardiotoxicity, clomipramine showed the best potency to inhibit SARS-CoV-2 spike glycoprotein pseudovirus-stimulated ACE2 internalization. Indeed, SARS-CoV-2 infection to human iPS-derived cardiomyocytes (iPS-CMs) and TMPRSS2-expressing VeroE6 cells were dramatically suppressed even after treatment with clomipramine. Furthermore, the combined use of clomipramine and remdesivir was revealed to synergistically suppress SARS-CoV-2 infection. Our results will provide the potentiality of clomipramine for the breakthrough treatment of severe COVID-19. A new pandemic of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in 2019 and rapidly spread worldwide in early 2020 1, 2 . Severe prognostic symptoms have become a global problem and the development of effective treatments and drugs is urgently needed 3, 4 . Coronaviruses are known for their impact on the respiratory tract, but SARS-CoV-2 can invade and infect the heart, and lead to a diverse spectrum of cardiac manifestations, including inflammation (myocarditis), arrhythmias, heart attack-like symptom, and heart failure 5, 6 . The tropism of organs has been studied from autopsy specimens. Sequencing data has revealed that SARS-CoV-2 genomic RNA was highest in the lungs, but the heart, kidney, and liver also showed substantial amounts 7 . In fact, above 1,000 copies of SARS-CoV-2 virus were detected in the heart from 31% patients who died by COVID-19 8 . The heart is one of the many organs with high expression of SARS-CoV-2 receptor, angiotensin converting enzyme 2 (ACE2) 9 . SARS-CoV use its spike (S) glycoprotein to bind with ACE2, and mediate membrane fusion and virus entry 10, 11 . In the process of ACE2 receptor-dependent syncytium formation (i.e., cell-cell fusion), the surface S proteins are cleaved and activated by transmembrane protease serine proteases (TMPRSSs) 11 . The ACE2-dependent SARS-CoV-2 virus entry is reportedly achieved through endocytosis regulated by phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) 12 , the main enzyme synthesizing phosphatidylinositol-3,5-bisphosphate (PI (3, 5) P2) in early endosome 13 , two-pore channel subtype 2 (TPC2) 12 , a major downstream effector of PI (3, 5) P2 14 , and cathepsin L 12, 15 , a cysteine protease that cleaves S protein to facilitate virus entry in lysosome. In this study, we focused on ACE2 internalization as a therapeutic target of severe COVID-19. Among 13 approved drugs that we have previously identified as potent inhibitor of cardiotoxicity caused by doxorubicin treatment 16, 17 , clomipramine, a tricyclic antidepressant 18 , was found to suppress SARS-CoV-2 invasion and infection in TMPRSS2-expressing VeroE6 cells and human iPS-derived cardiomyocytes (iPS-CMs). Clomipramine also synergistically suppresses SARS-CoV-2 virus infection with remdesivir, suggesting the potential as a breakthrough treatment for severe COVID-19. Muscular wasting, caused by atrophic remodeling of muscular tissues, is a major symptom of aging (i.e., sarcopenia) and cancer cachexia, and a risk factor for severe COVID-19 19 . We previously identified several approved drugs with potency to inhibit doxorubicin-induced muscular atrophy 20 , and the best potent ibudilast, an antiinflammatory drug used in the treatment of asthma and stroke, is now under progress of clinical trials for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients 21 . Therefore, we screened another type of drug that has an additional potency to inhibit SARS-CoV-2 spike (S) glycoprotein pseudovirus-stimulated ACE2 internalization. More than 80% of ACE2-EGFP-expressing HEK293T cells showed a marked ACE2 internalization by S protein (50 nM) treatment ( Figure 1A ). Among top 13 approved drugs, clomipramine, a tricyclic antidepressant that increases plasma serotonin levels 18 , showed the best potency to inhibit the S protein-induced ACE2 internalization ( Figure 1B , Table 1 ). Clomipramine inhibited SARS-CoV-2 pseudovirus infection in a concentration-dependent manner with an IC50 of 682  44 nM ( Figure 1C ). Desmethylclomipramine, a human metabolite of clomipramine, also inhibited the ACE2 internalization with an IC50 of 684  46 nM ( Figure 1C ). HiLyte Fluor 555-labeled S protein was incorporated into ACE2-EGFP-expressing HEK293T cells and inhibited by clomipramine ( Figure 1D ). Neither the currently proposed SARS-CoV-2 therapeutic agents 21-24 nor other tricyclic antidepressant agents showed as promising inhibitory effect as clomipramine ( Figure 1E , F). We also developed bioluminescence resonance energy transfer (BRET) assay that reflects relative distance between Renilla luciferase-tagged K-Ras (plasma membrane marker) and yellow fluorescent protein (venus)-tagged ACE2 ( Figure 1G ). The ACE2 internalization caused by pseudovirus infection determined by the decrease in BRET ratio (BRET) was suppressed by clomipramine in a concentrationdependent manner. ( Figure 1H ). In fact, HiLyte Fluor 555-labeled S protein was incorporated into human induced pluripotent stem cardiomyocytes (iPS-CMs) ( Figure 1I ), which was significantly suppressed by clomipramine treatment. These results suggest that clomipramine could be repurposed for the treatment with COVID-19 by inhibiting ACE2 internalization caused by SARS-CoV-2 pseudovirus infection. Clinically, it is important whether drug treatment after SARS-CoV-2 infection is effective. We confirmed that treatment with clomipramine 1 hour after pseudovirus infection also significantly suppressed the ACE2 internalization ( Figure 2A ). Therefore, we next Figure 2E ). Desmethylclomipramine also suppressed SARS-CoV-2 infection ( Figure 2F ). Plaque assay revealed that the SARS-CoV-2 virus viability was also reduced by clomipramine, but not ibudilast treatment ( Figure 2G ). Remdesivir is the RNA-dependent RNA polymerase inhibitor that is approved for the treatment with COVID-19 patients, although World Health Organization (WHO) Solidarity Trial results show little or no effect on hospitalized patients with COVID-19 25 . We next investigated how clomipramine inhibits ACE2 internalization caused by pseudovirus infection. The concentration-dependent increase in the number of ACE2 internalized cells due to S protein exposure was suppressed by clomipramine in a concentration-dependent manner, but the mode of inhibition was non-competitive ( Figure 3A ). Higher concentration (> 10 M) of clomipramine was required to significantly suppress the interaction between S protein and ACE2, and amitriptyline, another tricyclic antidepressant like clomipramine, never suppress the binding of S protein to ACE2 ( Figure 3B ). Clomipramine failed to reduce ACE2 enzyme activity ( Figure 3C ). These results suggest that clomipramine does not seemingly bind with ACE2 but noncompetitively inhibits ACE2 internalization in the cells. The receptor binding domain (RBD) of S protein reportedly activates the ACE2-mediated endocytic signal pathway, by which SARS-CoV-2 virus enters the susceptible cells 15 . We first attempted a structureactivity relationship analysis among tricyclic antidepressants with a structure similar to clomipramine, but it was difficult because none of the compounds showed significant inhibition of ACE2 internalization ( Figure 3D -F). An in silico docking analysis suggests that clomipramine interacts with the S protein at one end of its RBD (Figure 3 .G) and that the interacting residues are distinct from other candidate compounds ( Figure 3D -F). However, no apparent correlation was observed between the estimated binding energies and the internalization suppression ratio ( Figure 3D -E). These results suggest that clomipramine demonstrates a potent anti-COVID-19 effect by non-competitively inhibiting ACE2 internalization induced by S protein pseudovirus. Small molecule compounds that suppress SARS-CoV-2 virus infection and approved drugs that are expected to repurpose their indications for COVID-19 treatment have been identified one after another, but there is still few effective drug proven in clinical trials established by WHO 21 . Clomipramine, clinically applied as a tricyclic antidepressant, has been used in basic research as a pharmacological tool to inhibit clathrin-dependent endocytosis 26 , and therefore speculated to have antiviral activity 27 . We substantiated that clomipramine suppresses SARS-CoV-2 virus infection and proliferation in human iPS-CMs by preventing ACE2 internalization (Figure 1, 2) . In addition to a long half-life pharmacodynamics of clomipramine, its metabolite (desmethylclomipramine) had the similar inhibitory effect of SARS-CoV-2 infection (Figure 1, 2) , suggesting that the antiviral effect of clomipramine lasts for a long time. In the process of SARS-CoV-2 virus incorporation into cells with ACE2, serine proteases-dependent plasma membrane pathway (targeted by nafamostat and cepharanthine) and cathepsin-dependent endosomelysosome fusion pathway (targeted by chloroquine) have been attracted attention as therapeutic targets. In fact, several candidate compounds have also been identified 21, 22 . On the other hand, we have not clarified the molecular mechanism underlying suppression of ACE2 internalization by clomipramine. However, while clomipramine demonstrated a potent inhibition of ACE2 internalization due to pseudovirus infection, no drug with the same or better inhibitory effect as clomipramine was obtained ( Figure 1 ). This result may explain why clomipramine potently suppresses SARS-CoV-2 virus infection. As to the possibility of the improvement of severe COVID-19 by clomipramine, we suggest an anti-inflammatory effect of clomipramine like ibudilast 17 . We have previously reported that transient receptor potential canonical (TRPC) 3 protein, a major component of receptor-activated cation channels, contributes to pathological myocardial atrophy caused by anti-cancer drug treatment 16 , by promoting NADPH oxidase (Nox) 2dependent reactive oxygen species (ROS) production on cardiac plasma membrane through interacting with Nox2 and preventing Nox2 from ER-associated degradation 20 . Severe COVID-19 symptoms include abnormalities of many organs other than the heart, such as pneumonia, ARDS, olfactory disorder, dysgeusia, vasculitis, headache, and fever 28, 29 . Particularly, ibudilast, identified as the best potent inhibitor of TRPC3-Nox2 complex formation, is now under progress of clinical trials for the treatment of ARDS in COVID-19 patients 21 . We have confirmed that clomipramine attenuated the doxorubicininduced cardiomyocyte atrophy by inhibiting TRPC3-Nox2 complex formation (data not shown). Thus, future studies using COVID-19 model animals will clarify whether clomipramine is effective for the prevention and treatment of severe COVID-19. Although clomipramine showed a concentration-dependent inhibition of SARS-CoV-2 infection, its mode of action was not competitive inhibition. In silico docking analysis predicts that clomipramine interacts with the S protein at the end of the RBD domain, whereby inhibiting ACE2-S protein interaction at higher concentration. However, the binding is weak and therefore this might not fully explain the potent inhibitory effect on SARS-CoV-2 infection by clomipramine. Further study is necessary to identify a molecular target by which clomipramine inhibits ACE2 internalization caused by SARS-CoV-2 virus. The ACE2 upregulation due to exposure to risk factors for severe COVID-19 is considered as a compensatory mechanism for attenuating the action of angiotensin (Ang) II. Clomipramine does not affect basal ACE2 expression level, but suppresses pathological ACE2 upregulation caused by exposure to risk factors. Additionally, since clomipramine has no impact on ACE2 enzyme activity, it is considered that clomipramine has little effect on AngII and Ang1-7 / Mas receptor signaling pathways in normal cells. On the other hand, it has been reported that Ang1-7 / Mas receptor signaling is attenuated in COVID-19 with ACE2 internalization and degradation 30 . Since clomipramine suppresses ACE2 internalization without reducing ACE2 enzyme activity, clomipramine is also expected to contribute to the maintenance of Ang1-7 / Mas receptor signaling after infection. In conclusion, this study establishes clomipramine as a potent anti-SARS-CoV-2 agent in human cardiomyocytes. As the co-treatment of clomipramine with remdesivir synergistically suppresses SARS-CoV-2 infection, repurposing of clomipramine will be a promising therapeutic strategy for the prevention and treatment of severe COVID-19. Imaging was performed on a BZ-X800 microscope (Keyence). ACE2-internalized cells were counted in each section and normalized without S protein as a control. Recombinant SARS-CoV-2 spike protein (S protein) were purified using the baculovirussilkworm system 32 For immunohistochemistry, iPS-CMs were fixed in 4% paraformaldehyde and then washed twice in PBS. The fixed cells were permeabilized and blocked using 0.1% Triton X-100 and 1% BSA in PBS for 1 hour at room temperature. Alexa Fluor 488 phalloidin (Thermo Fisher Scientific) was diluted with PBS and reacted for 1 hour at room temperature. After mounting with ProLong Diamond Antifade Mountant containing DAPI (Invitrogen), images were captured using a confocal laser-scanning microscope (LSM700, Zeiss, Germany). Plaque assay was performed essentially as described 33 .Infection medium of TMPRSS2-expressing VeroE6 cells after SARS-CoV-2 virus infection was diluted by DMEM supplemented with 2% FBS and 1% penicillin and streptomycin. This sample spread on an agar plate with 2% FBS and 1% methylcellulose and cultured at 37 °C for 3 days. VeroE6 cells on the plate were fixed in 10% neutral-buffered formalin (Fujifilm Wako Chemicals, Tokyo, Japan), and strained with methylene blue. Numbers of the plaque in each well were counted to calculate infective per one ml of the samples. Human iPS-CMs (3×10 4 cells/well) were seeded. SARS-CoV-2 were added at MOI 2.5. Forty-eight hours after infection, cells were fixed in 4% paraformaldehyde. The fixed cells were incubated with anti-SARS-CoV-2 nucleocapside (1:100; GeneTex), anti-SARS spike glycoprotein (1:100; abcam) and DAPI. Images were captured using a Nikon A1 confocal microscope (Nikon). The ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit (BPS Bioscience #79936) was purchased and measured the binding of ACE2 and SARS-CoV-2 Spike in the presence and absence of inhibitors, according to the manufacturer's instructions. The ACE2 Inhibitor screening assay kit (BPS Bioscience #79923) was purchased and measured the exopeptidase activity of ACE2 in the presence and absence of inhibitors, following the manufacturer's instructions. The bindings of 22 candidate compounds, including clomipramine, toward the receptor binding domain (RBD) of SARS-CoV-2 Spike protein were analyzed using SMINA program with its own score function (SMINA score) 34 . The structure of the receptor (RBD of Spike protein) was taken from the crystal structure (PDBID: 6m0j) 35 Figure 4D . The estimated binding energies of the best poses for 22 compounds were further refined by minimizing using ad4_scoring, which corresponds to the AutoDock 4 score including a desolvation fee energy term (Supplemental Figure 5B ). Clomipramine, voriconazole, clopidogrel, trifluoperazine, androsterone, nifedipine, ibuprofen, loxoprofen and fluvoxamine were purchased from Fujifilm Wako Chemicals, (Tokyo, Japan). Ibudilast, lynestrenol, pyrilamine, tolnaftate, mifepristone, ticlopidine, nafamostat, chlorpromazine, nelfinavir, diclofenac, indomethacin, nintedanib and pirfenidone were purchased from Tokyo Chemical Industry (Tokyo, Japan). Fipexide, ciclesonide and desmethylclomipramine were purchased from sigma (St.louis, MO, USA). Cepharanthine was purchase from Cayman chemical (Michigan, USA). G*Power3.1.9.2 software was used to calculate the sample size for each group. All results are presented as the mean ± SEM from at least 3 independent experiments and were considered significant if P < 0.05. Statistical comparisons were made using unpaired t test for two-group comparisons or using one-way ANOVA with Tukey's post hoc test for comparisons among 3 or more groups when F achieved was P < 0.05, and there was no significant variance in homogeneity. Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Software, LaJolla, CA). Some results were normalized to control to avoid unwanted sources of variation. A Novel Coronavirus from Patients with Pneumonia in China A novel coronavirus outbreak of global health concern Clinical features of patients infected with 2019 novel coronavirus in Wuhan All In' : a pragmatic framework for COVID-19 testing and acting on a global scale Cardiovascular Manifestations of COVID-19 COVID-19 can affect the heart Multiorgan and Renal Tropism of SARS-CoV-2 Association of Cardiac Infection with SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 Angiotensin-Converting enzyme 2 is a functional receptor for the SARS coronavirus SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARSCoV-2 infection TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes Clomipramine: An Overview of its Pharmacological Properties and a Review of its Therapeutic Use in Obsessive Compulsive Disorder and Panic Disorder COVID-19: a major cause of cachexia and sarcopenia? TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 Repurposing drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2 Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial Repurposed antiviral drugs for Covid-19 -interim WHO solidarity trial results The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Olfactory Dysfunction in COVID-19: Diagnosis and Management Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injoury Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system Viral concentration determination through plaque assays:using traditional and novel overlay systems Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking Exercise Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor The PyMOL Molecular Graphics System PubChem in 2021: New data content and improved web interfaces RDKit: Open-source cheminformatics We appreciate the technical assistance from The Research Support Center, Research Yu.K., K.N., S.R., K.M. and M.N. wrote the paper, Ya.K. and Yu.